IDH1 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas is a research paper published in Journal of Neuro-Oncology (2022). On theSindex it has a DataRank of 0.581. It has been cited 47 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.581
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Cancer Institute
Grant: P30CA125123
National Cancer Institute
Grant: K08CA241651
National Cancer Institute,United States
Grant: R01CA216426
Cancer Prevention and Research Institute of Texas
Grant: RP170005
Brain Cancer SPORE
Grant: 2P50CA127001
NCI NIH HHS
Grant: P50 CA127001
NCI NIH HHS
Grant: R01 CA220297
National Institutes of Health
Grant: 3P30CA125123-09S3
Baylor College of Medicine Cancer Center
National Institutes of Health
Grant: 5R01CA220297-02
Racial Disparity in Bladder Cancer and Identification of Altered Metabolism in African American Compare to European Bladder Cancer
National Institutes of Health
Grant: 3P50CA127001-10S1
SPORE in Brain Cancer
National Institutes of Health
Grant: 5K08CA241651-02
Development and Validation of a CSF Liquid Biopsy for Molecular Characterization and Monitoring of Patients with Central Nervous System Tumors
National Institutes of Health
Grant: 5R01CA216426-05
Identify the DNA Adduct and Associated Metabolic Alterations in Bladder Cancer of Smokers
FWCI
6.12
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 6 of The genomic alterations in glioblastoma influence the levels of CSF metabolites
Additional file 6 of The genomic alterations in glioblastoma influence the levels of CSF metabolites
Additional file 5 of The genomic alterations in glioblastoma influence the levels of CSF metabolites
Additional file 5 of The genomic alterations in glioblastoma influence the levels of CSF metabolites
Additional file 3 of The genomic alterations in glioblastoma influence the levels of CSF metabolites
Additional file 3 of The genomic alterations in glioblastoma influence the levels of CSF metabolites
Additional file 1 of The genomic alterations in glioblastoma influence the levels of CSF metabolites
Additional file 1 of The genomic alterations in glioblastoma influence the levels of CSF metabolites
Additional file 2 of The genomic alterations in glioblastoma influence the levels of CSF metabolites
Additional file 4 of The genomic alterations in glioblastoma influence the levels of CSF metabolites
Additional file 4 of The genomic alterations in glioblastoma influence the levels of CSF metabolites
Additional file 2 of The genomic alterations in glioblastoma influence the levels of CSF metabolites